The FDA concluded that UniQure's experimental Huntington’s treatment was not providing benefit for patients based on existing clinical data ...
The FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results